For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 18,474 | 23,668* | 19,270 | 17,724 |
| General and administrative | 8,791 | 5,791* | 4,656 | 4,081 |
| Total operating expenses | 27,265 | 29,458 | 23,926 | 21,805 |
| Loss from operations | -27,265 | -29,458* | -23,926 | -21,805 |
| Interest and other income, net | 3,748 | 4,031* | 2,308 | 2,394 |
| Net loss | -23,517 | -25,427* | -21,618 | -19,411 |
| Unrealized loss on marketable securities | -892 | 94* | 143 | -42 |
| Reclassification of net gains included in net loss | - | 14* | - | - |
| Total other comprehensive loss | -892 | 80* | 143 | -42 |
| Total comprehensive loss | -24,409 | -25,348 | -21,475 | -19,453 |
| Basic EPS | -0.5 | -0.605 | -0.63 | -0.58 |
| Diluted EPS | -0.5 | -0.605 | -0.63 | -0.58 |
| Basic Average Shares | 46,576,204 | 41,873,294 | 34,198,597 | 33,446,385 |
| Diluted Average Shares | 46,576,204 | 41,873,294 | 34,198,597 | 33,446,385 |
MBX Biosciences, Inc. (MBX)
MBX Biosciences, Inc. (MBX)